Premium Nahrungsergänzungsmittel | artgerecht

Acylcarnitine Profile – Meaning and Diagnostics

The acylcarnitine profile is a diagnostic blood test used to detect inherited metabolic disorders. It measures acylcarnitines in the blood and is a key component of newborn screening programs.

Regular tips about health Regular tips about health

Things worth knowing about "Acylcarnitine Profile"

The acylcarnitine profile is a diagnostic blood test used to detect inherited metabolic disorders. It measures acylcarnitines in the blood and is a key component of newborn screening programs.

What Is the Acylcarnitine Profile?

The acylcarnitine profile is a laboratory test that measures a broad range of acylcarnitines in the blood. Acylcarnitines are compounds formed when fatty acids and amino acids are broken down during metabolism and bind to the transport molecule carnitine. By analyzing this profile, clinicians can determine whether specific metabolic enzymes are functioning properly or whether a defect is causing a harmful accumulation of metabolic intermediates.

The acylcarnitine profile is primarily used in expanded newborn screening to detect inherited metabolic diseases before any symptoms appear. Early diagnosis allows for prompt treatment, which can prevent severe health complications or life-threatening metabolic crises.

Method and Procedure

The acylcarnitine profile is typically analyzed using tandem mass spectrometry (MS/MS). This highly sensitive technique allows dozens of different acylcarnitines to be measured and distinguished simultaneously within minutes. The sample material usually consists of a few drops of blood spotted onto a special filter card, known as a dried blood spot card or Guthrie card.

Blood collection: Heel prick in newborns or venous blood draw in older patients
Sample preparation: Application to a dried blood spot filter card
Analysis: Tandem mass spectrometry in a specialized laboratory
Interpretation: Comparison of measured acylcarnitine levels with reference values

Clinical Significance and Diagnostic Relevance

The acylcarnitine profile enables the diagnosis of a wide range of inherited metabolic disorders. The most important categories include:

Fatty Acid Oxidation Disorders

In these conditions, the body is unable to fully utilize fats as an energy source. Common examples include:

MCAD deficiency (Medium-Chain Acyl-CoA Dehydrogenase deficiency): the most common fatty acid oxidation disorder
VLCAD deficiency (Very Long-Chain Acyl-CoA Dehydrogenase deficiency)
LCHAD deficiency (Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase deficiency)
Carnitine palmitoyltransferase deficiency (CPT I and CPT II)

Organic Acidemias

These disorders affect amino acid breakdown and lead to the accumulation of organic acids in the body. Examples include:

Propionic acidemia
Methylmalonic acidemia
Isovaleric acidemia
Glutaric aciduria type I

Amino Acid Disorders

Certain amino acid metabolism disorders can also be identified or confirmed through the acylcarnitine profile, such as maple syrup urine disease (MSUD).

Interpretation of Results

Interpreting the acylcarnitine profile requires specialized expertise. Altered acylcarnitine levels can indicate a specific enzyme deficiency, as each disorder produces a characteristic pattern of abnormal acylcarnitines. For example, elevated C8-acylcarnitine (octanoylcarnitine) levels are a hallmark finding in MCAD deficiency, while elevated long-chain acylcarnitines suggest VLCAD or LCHAD deficiency.

Abnormal results prompt further investigations, such as enzyme activity assays or molecular genetic testing, to confirm the diagnosis.

Newborn Screening

In Germany, expanded newborn screening -- which includes the acylcarnitine profile -- is mandated by law and is typically performed on the 2nd to 3rd day of life. Similar programs are in place in Austria, Switzerland, and many other countries worldwide. The goal is to identify treatable conditions as early as possible and prevent life-threatening metabolic crises.

References

Gemeinsamer Bundesausschuss (G-BA): Kinder-Richtlinie - Neugeborenenscreening auf angeborene Stoffwechselerkrankungen. Berlin, 2021.
Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genetics in Medicine. 2008;10(2):151-156.
Kolker S et al. Diagnosis and management of fatty acid oxidation disorders and organic acidurias. AWMF Clinical Guideline, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.